Article | May 4, 2020

Key Considerations For Labeling Your Cell Or Gene Therapy

By Abdul Ally and Amy Hendricks, Thermo Fisher Scientific

Pharmaceutical Packaging

With the continued expansion of the pharmaceutical industry’s global footprint and the growing complexity of today’s drug products, ensuring their safe delivery to patients is becoming more challenging than ever before. Not only must a sponsor secure a supply chain that can support their commercial goals, but they must also safeguard their products using viable packaging and labeling strategies. Without them, they run the risk of their drug being delivered outside of its specifications and/or without the information necessary for it to be properly identified and used during clinical trials.

This can be particularly difficult for those products shipped within the cryogenic temperature range of -150° to -196° C, such as cell and gene therapies. Time out of temperature can have a major impact on the efficacy of the therapy and, ultimately, its clinical outcomes. As sponsors focus on maintaining the temperature range required for these therapies, they must also keep in mind the challenges these temperatures can present when properly labeling personalized therapies for clinical trial distribution.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: